NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

CompletedN/A

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions: Pertussis

Interventions: Pentacel® (DTaP-IPV/Hib), Other Pertussis Vaccines

Countries: United States

The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® vaccine who acquire pertussis disease to the proportion of such persons vaccinated with any other Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccine who acquire pertussis disease. Primary Objective: To determine the rates and relative risk of pertussis disease among Surveillance Population members who have received Pentacel vaccine or another pertussis vaccine.

Eligibility overview

Sex: ALL

Age: — to 59 Months

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria :

* Persons will be under surveillance for this study whenever the following three conditions are true: the individual resides in Wisconsin, is age birth through 59 months, and is within the surveillance period of 01 October 2009 through 30 September 2014 (or as extended in order to accrue 61,761 person years of Pentacel vaccine exposure).

Exclusion Criteria :

* Not applicable

Locations (2)

Madison, Wisconsin, United States
Madison, Wisconsin, United States